Enhancing protein therapeutics
                                 through selective modification

Advanced Proteome Therapeutics is developing a new technology platform that can shorten the time-to-market for the commercialization of protein therapeutics. This patent-pending technology platform incorporates a novel method for the selective modification of proteins that affords opportunities to improve key therapeutic properties. The technology has the potential of improving the properties of a growing list of off-patent protein therapeutics resulting in the development of investigational new drugs. APT’s commercialization strategy is to modify selected protein therapeutics, demonstrate their improved properties though in-vivo testing, and then partner with established pharmaceutical companies.

The Company’s technology features a method of attaching efficacy-enhancing entities to proteins to improve their therapeutic properties. APT’s technology exploits molecular chaperones that are capable of guiding enhancing entities to sites on the protein that are key to improving such properties. A unique, commercially and clinically attractive feature of the technology is that it does not require changing or mutating the protein’s natural sequence since such modifications might induce undesirable immunological reactions. 

Advanced Proteome Therapeutics’ technology holds forth the prospect of rapidly generating therapeutic proteins with enhanced properties, in the fastest growing segment of the market for ethical drugs. Of particular interest are commercially viable protein therapeutics with established markets which are candidates for redevelopment that will benefit the patient population and create new patent life.

Our technology platform provides APT with the capability to generate targeted libraries with distinct chemical properties, to screen for entities with the optimal characteristics for each application, and to reproducibly prepare suitable candidates that emerge from the screen for advanced testing.   The Company’s technology is applicable not only to protein drugs, but to potentially a broad range of protein products in the fields of diagnostics and proteomics.